was claimed that they would allow reliable estimation of the treatment effect based on blinded data by using information about the block length of the randomisation procedure. If this would hold true, it would be difficult to preserve blindness without taking further measures. The suggested procedures apply to continuous data and their characteristics were illustrated by applying them to a single simulated data set per scenario considered. We investigate the properties of these methods more thoroughly by repeated simulations per scenario. Furthermore, a method for blinded treatment effect estimation in case of binary data is proposed, and blinded tests for treatment group differences are developed both for continuous and binary data. We report results of comprehensive simulation studies that investigate the features of these procedures. It is shown that for sample sizes and treatment effects which are typical in clinical trials, no reliable inference can be made on the treatment group difference which is due to the bias and imprecision of the blinded estimates.
INTRODUCTION
One of the most important issues in the design of clinical trials is the implementation of procedures that eliminate or minimise bias. Blinding and randomisation are generally considered to be the most important techniques in this context   1 . While randomisation eliminates bias in treatment assignment, blinding minimises the risk of trial personnel or patients being aware of the assigned intervention and thus from being influenced by this. Knowledge of treatment group assignment may, beside others, affect the response of the participants, influence the use of ancillary interventions of the investigators, or lead to a differential judgment of the outcome by the assessors  
. But even if
individual treatment assignments are unknown, knowledge of the size of the treatment effect during an ongoing trial may influence the attitude of anyone involved in the trial and may thus lead to the occurrence of bias by mechanisms as such described above.
For this reason, regulatory guidelines strongly demand that the results of interim analyses are not disseminated to the personnel and patients involved in a trial   1, 3 . It is therefore standard that any comparison between treatment groups that is performed midcourse of a trial is assigned to an independent committee which maintains the results strictly confidentially   4 . The only information that is disseminated beyond the small circle of committee members is whether the trial was stopped or continued. As a further measure, information on who is assigned to which treatment group is not included in the trial database while the study is ongoing but is kept separately with special access rights.
Usually, general information on the implemented randomisation procedure is given in the protocol, such as the method used for random sequence generation or prognostic variables that are taken into account in stratified randomisation. Quite frequently, block randomisation is applied to minimise the risk of obtaining an undesirable sample size imbalance between the treatment groups. In order to prevent from the possibility of predicting the assignment of future patients from guessed or known assignments of patients already allocated, it is recommended not to specify the block length in the protocol   5 . However, trial statisticians are generally aware of the block lengths andas they have access to the trial database -they also know the order in which the patients were recruited. Therefore, they are aware of which patients are in which block. It is evident that for extreme outcome scenarios this knowledge can be used to derive information about the treatment effect even if the individual treatment group allocation remains blinded. For example, in the case of a binary endpoint "event yes / no" where in every block either the event occurs for all patients or does not occur for any patient, it is clear that there is no difference in treatment effect between the groups. The question arises, whether reliable conclusions about the treatment effect can be drawn from the blinded data also in more realistic situations. The message given in a recent paper by van der Meulen   6 raises hopes or fears -depending on the perspective -that this would be possible. In the abstract of [6] it was claimed that when randomisation is done using permuted blocks "statistical inference of the treatment effects can be conducted" before unblinding "yielding consistent and rather precise estimates"   6, . 479 p . In the light of the above-mentioned fact that the integrity of the trial is questioned if information about the extent of the treatment effect becomes known and if actions are taken based on this information during the course of a trial, this would create serious problems.
Other methods that allow a blinded estimation of the treatment effect have been proposed in the literature before. In the framework of blinded sample size re-estimation, Gould and Shih [7] suggested a method to estimate the within-group variance of normally distributed data. This procedure is based on an EM algorithm and does not make use of information about the randomisation. It provides not only an estimate of the within-group variance but also of the treatment effect. It was shown that this approach exhibits some major deficits and is not appropriate for sample size re-estimation based on the blinded variance estimate [8, 9] . Waksmann [10] corrected the Gould-Shih procedure such that now the resulting estimates converge to the ML estimates. He investigated the characteristics of the resolved method in a thorough simulation study and found that for sample sizes and treatment effects that usually occur in clinical trials, the estimates of the treatment group difference are not accurate enough to be of practical value. The same conclusion was drawn by Xing and Ganju [11] for the procedure they derived by making use of the knowledge of the randomisation block length. Their primary focus was the construction of a blinded variance estimator for the purpose of blinded sample size re-estimation in case of continuous data. They briefly mention that a blinded estimator of the treatment effect can be obtained as a by-product, based on the difference between the pooled one-sample variance estimator for all data and their blinded within-group variance estimator (which is a multiple of the variance of the block means). Based on heuristic arguments and simulation results, Xing and Ganju concluded that "there is no risk of unblinding the trial" because "the variation in the estimate of 2  is large enough to be practically useless". In contrast to the other references mentioned above, van der Meulen [6] focuses on estimation of the treatment effect using estimators based on all available effect information in the blinded data.
Interestingly, he derived blinded moment and ML estimators of the treatment group difference for continuous data that use the knowledge of the block length applied in randomisation. His work on the estimators is therefore a good basis to investigate the amount of effect-information contained in blinded data. Besides, van der Meulen's [6] investigations suggest that the blinded estimates of the variance he derived with the ML method are more precise than the blinded treatment effect estimates. Recently, Ganju and Xing [12] discussed specifically the blinded treatment effect estimation of van der
Meulen and concluded that "the blinded method is refined enough for blinded variance estimation but blunt enough for inferring efficacy". 
is the within-block difference in block i and
Z is therefore the mean in block i. The between-block variation (i.e., the variance of block means) can thus be expressed as for all sample sizes, while underestimation occurs for 1   (with the only exception of 4 l  and total sample sizes smaller than 40). As could be expected, the extent of bias is for the same sample sizes generally higher for block size 4 l  than for block size 2. For 0.5   , a positive bias is observed for small sample sizes which changes to a negative bias when the sample size is increased. The shift from overestimation to underestimation occurs for higher sample sizes for block size 4 l  as compared to 2 l  . In all considered situations, the mean estimates resulting from the moment estimator are slightly smaller than those for the ML estimator, but the difference is negligible for practical purposes. For 0   , the bias approaches zero only for sample sizes which would have been used if the relevant effect assumed at the planning stage was much smaller than the true treatment effect  . As a reviewer noted, this result is also reflected in Table 1 of van der Meulen's paper [6] : For the data set he used, the treatment effect is estimated precisely from blinded data only when the trial has extremely high power (> 99%); see also [12] . cause to the suspicion of a non-zero treatment effect. Figure 3 shows that such estimates occur with considerable probability only for at least as extreme true treatment effects.
As a consequence, for treatment group differences and sample sizes which are common in clinical trials, a differentiation between various extents of  based on the blinded moment or ML estimator is not possible. This uncertainty about the actual amount of  is a consequence of the substantial positive bias of the blinded estimators for the situation 0   combined with a high variability of the estimates.
In order to study the sensitivity of our findings to deviations from the normal distribution we conducted simulations with non-normal distributions including distributions with heavy tails (t-distributions with small number of degrees of freedom) and skewed distributions (e.g. log normal distribution). We found that the results for the moment estimator are robust against such deviations. However, the ML estimator was sensitive to deviations from normality as expected with at times severe downwards bias in estimation of the treatment effect Δ. The general observation for non-normal distributions was that the performance of the blinded estimators is not better as seen for normal data. A differentiation between various extents of  based on the blinded moment or ML estimator is even more difficult.
Blinded tests for treatment effect
From the above mentioned formulae for the within-block variation and the betweenblock variation, a blinded F-test can be derived. As the F-test and the moment estimator are closely related, it cannot be expected that this test will be more revealing than the findings presented in Section 2.1, but is an alternative way to look at this problem. For In practice, one would usually try to learn from the blinded data while the study is still ongoing. Hence, the blinded test would be applied before the data of all * n patients are available. As a consequence, the required factors by which the true effect has to exceed the one used for sample size calculation to achieve a power of 50 or 80 per cent for the blinded test are even higher as those reported above.
These considerations show that the blinded F-test has reasonable power only when the true treatment effect is several times larger than the clinically relevant effect assumed in the sample size calculation of the study, i.e. if the study is an overpowered study from a retrospective point of view. Though there is a possibility for this to happen, this is a very rare event in clinical practice. 
Blinded estimation of treatment effect
In case of binary data, we consider the ML estimator and the moment estimator for blinded estimation of the treatment effect. We will see that this approach leads to a simple expression for the estimator. In order to avoid repetition we restrict the presentation here to block length 2 l  as in this situation most information can be drawn from the blinded data thus marking the best case scenario for the performance of blinded estimation methods.
The information included in blinded binary data is the number of events that occurred in each block and the order they occurred. In the case of block size 2 l  , the be seen after some calculation that the log likelihood is maximised for
(which is the observed overall event rate) and for
Hence, the blinded ML estimator for
Another possibility is to apply the moment estimator presented in Section 2.1 directly to binary data. In case of binary data and block length 2  l we find ) 2 /( to speculate whether the true treatment effect might be different from zero. However, such large estimated effects occur in turn only for very large true differences with noticeable probability. In summary, it can be concluded that for treatment effects and sample sizes which are usually met in clinical trials different values of  cannot be distinguished by blinded moment or ML estimation.
Blinded tests for treatment effect
In Section 2.2 we introduced the F-test 
where ( ) floor x is the largest integer that is less than or equal to x, replications.
As can be seen from Figure 6 the risk differences need to be 2 to 4 times larger than anticipated in order to obtain a power in the range of 0.5 to 0.8 for the considered 20 combinations of rate differences and overall event rates. This is in keeping with similar effects observed in Figure 4 .
Alternative test statistics could be used for the permutation test. For instance, the MLE of the treatment difference given above or the likelihood ratio test (LRT) statistic would make good choices. Both statistics lead to tests equivalent to the one used above.
DISCUSSION
We saw that it is possible to construct both for continuous and for binary data estimators and should be carefully weighted against its merits before application. Secondly, details about the randomisation procedure should not be described in the protocol but specified in a separate document that is withheld from all persons involved in the study. Furthermore, the process of generating the allocation sequence should be separated from the personnel that has access to the trial database.
By this, it can definitely be avoided that knowledge about the randomisation scheme is used to derive information about the treatment effect from the blinded study data by application of the methods described above.
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In case of a reasonable possibility of an overpowered study, the introduction of an interim analysis that allows for early stopping in case of overwhelming efficacy might be an option in addition to the measures mentioned above. This is a much more efficient way of conducting the trial than trying to recover treatment effect estimates from blinded data.
In summary, for all proposed approaches for blinded assessment of the treatment effect it holds true what Waksman states on the corrected EM algorithm based method, namely "it is interesting to note that the procedure can accurately and precisely estimate the difference when either the sample size or the true difference is sufficiently large"   
